fluorouracil has been researched along with Bilirubinemia in 15 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 7.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI." | 7.81 | [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 5.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 3.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI." | 3.81 | [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015) |
| "Gemcitabine/capecitabine can be given at the standard dose in patients with severe hyperbilirubinemia, though the present data suggest that gemcitabine's activity may be limited due to poor intracellular activation." | 3.80 | Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. ( Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH, 2014) |
| "To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping." | 3.80 | FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "In most cases, hyperbilirubinemia was associated with concomitant alterations in other hemolytic parameters." | 2.71 | Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. ( Cassidy, J; Filipovic-Ljeskovic, I; Jelic, S; Nikolic-Tomasevic, Z; Tomasevic, Z, 2005) |
| "Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 1.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joerger, M | 1 |
| Huitema, AD | 1 |
| Koeberle, D | 1 |
| Rosing, H | 1 |
| Beijnen, JH | 1 |
| Hitz, F | 1 |
| Cerny, T | 1 |
| Schellens, JH | 1 |
| Gillessen, S | 1 |
| Yeh, YS | 2 |
| Huang, ML | 1 |
| Chang, SF | 1 |
| Chen, CF | 1 |
| Hu, HM | 1 |
| Wang, JY | 2 |
| Kit, OI | 1 |
| Vladimirova, LY | 1 |
| Vodolazhskiy, DI | 1 |
| Abramova, NA | 1 |
| Dvadnenko, KV | 1 |
| Ho, MY | 1 |
| Kennecke, HF | 1 |
| Renouf, DJ | 1 |
| Cheung, WY | 1 |
| Lim, HJ | 1 |
| Gill, S | 1 |
| Huang, CW | 1 |
| Ma, CJ | 1 |
| Tsai, HL | 1 |
| Chen, CW | 1 |
| Huang, MY | 1 |
| Lu, CY | 1 |
| Wu, JY | 1 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 1 |
| Schüll, B | 1 |
| Scheithauer, W | 1 |
| Kornek, GV | 1 |
| Sakamoto, J | 1 |
| Kondo, Y | 2 |
| Takemiya, S | 1 |
| Sakamoto, N | 1 |
| Nishisho, I | 1 |
| Terashima, M | 1 |
| Sato, A | 1 |
| Taguchi, T | 1 |
| Eichbaum, MH | 1 |
| Schneeweiss, A | 1 |
| de Rossi, T | 1 |
| Bastert, G | 1 |
| Nikolic-Tomasevic, Z | 1 |
| Jelic, S | 1 |
| Cassidy, J | 1 |
| Filipovic-Ljeskovic, I | 1 |
| Tomasevic, Z | 1 |
| Santasusana, JM | 1 |
| García López, JL | 1 |
| García, JJ | 1 |
| Carbonero, AI | 1 |
| Plazas, JG | 1 |
| Rovira, PS | 1 |
| Martos, CF | 1 |
| Guzmán, MC | 1 |
| Jericó, JF | 1 |
| Delgado, FJ | 1 |
| Espinosa, JC | 1 |
| Muñoz, ML | 1 |
| Aguilar, EA | 1 |
| Valera, JS | 1 |
| García Ribas, I | 1 |
| Mena, AC | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Martínez Banaclocha, N | 1 |
| Gallego Plazas, J | 1 |
| Carrato Mena, A | 1 |
| Gupta, B | 1 |
| LeVea, C | 1 |
| Litwin, A | 1 |
| Fakih, MG | 1 |
| Kemeny, N | 1 |
| Seiter, K | 1 |
| Martin, D | 1 |
| Urmacher, C | 1 |
| Niedzwiecki, D | 1 |
| Kurtz, RC | 1 |
| Costa, P | 1 |
| Murray, M | 1 |
1 review available for fluorouracil and Bilirubinemia
| Article | Year |
|---|---|
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
5 trials available for fluorouracil and Bilirubinemia
| Article | Year |
|---|---|
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2005 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
9 other studies available for fluorouracil and Bilirubinemia
| Article | Year |
|---|---|
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bili | 2017 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
Endoscopic stenting of the common bile duct allows successful treatment of a breast cancer patient with excessive liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Common | 2004 |
[Patient with haemolytic anemia and treatment with capecitabine. Review of one case and literature].
Topics: Adult; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecita | 2006 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2007 |